Citadel Advisors
BCTXL

Citadel Advisors’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

Citadel Advisors’s Portfolio BCTXL Stock Details BCTXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$717K Sell
895,864
-152,895
-15% -$141K ﹤0.01% 9019
2026
Q1 		$1.05M Buy
+1,048,759
New +$1.11M ﹤0.01% 7550

Other funds holding BCTXL

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Citadel Advisors's BCTXL Position: Q2 2026 in Review

Citadel Advisors reduced its BriaCell Therapeutics Warrant (BCTXL) stake by 15% in Q2 2026, selling an estimated $141K and leaving 895,864 shares worth $717K. The position accounts for ﹤0.01% of the portfolio, ranked #9019.

Citadel Advisors first reported a position in BCTXL in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.05M in Q1 2026. 10 funds tracked by Wall St. Rank hold BCTXL as of Q2 2026.

  • Citadel Advisors held 895,864 shares of BriaCell Therapeutics Warrant worth $717K as of Q2 2026.
  • Citadel Advisors sold 152,895 BriaCell Therapeutics Warrant shares in Q2 2026, an estimated $141K.
  • BriaCell Therapeutics Warrant made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #9019 holding.
  • Citadel Advisors first reported a position in BriaCell Therapeutics Warrant in Q1 2026 and has held it in 2 quarters since.
  • Citadel Advisors's BriaCell Therapeutics Warrant position peaked at $1.05M in Q1 2026.
  • 10 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.